Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torcetrapib/Atorvastatin in Fredrickson Types IIa and IIb Dyslipidemias
NCT00137462Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of torcetrapib in familial hypercholesterolemia (FH) and Familial Combined Hyperlipidemia (FCH) (2 arms), sponsored by Pfizer. Primary endpoint: Change in lipid parameters (HDL, LDL) at 12 months. Started Nov 2004; status: completed.
02
Drugs
torcetrapib
03
Conditions
familial hypercholesterolemia (FH)Familial Combined Hyperlipidemia (FCH)
Beyond the preview
Go deeper on NCT00137462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137462.